HELP
HEALTHCARECybin Inc
$5.54+0.32 (+6.13%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving HELP Today?
No stock-specific AI insight has been generated for HELP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.29$9.83
$5.54
Fundamentals
Market Cap$276M
P/E Ratio—
EPS$-4.30
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume716K
Avg Volume (10D)—
Shares Outstanding49.9M
HELP News
20 articles- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·May 4, 2026
- CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthYahoo Finance·Apr 30, 2026
- Helus Pharma to Participate at the 29th Annual Milken Institute Global ConferenceYahoo Finance·Apr 30, 2026
- Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthYahoo Finance·Apr 28, 2026
- Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?Yahoo Finance·Apr 25, 2026
- FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers GainYahoo Finance·Apr 24, 2026
- Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen BrannanYahoo Finance·Apr 23, 2026
- Trump Signed a Psychedelic Drugs Order—and These 4 Stocks SurgedYahoo Finance·Apr 20, 2026
- Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health ConditionsYahoo Finance·Apr 20, 2026
- Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive OfficerYahoo Finance·Apr 20, 2026
- Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental IllnessYahoo Finance·Apr 20, 2026
- Cybin Insider Ups Holding By 105% During YearYahoo Finance·Apr 19, 2026
- Trump Trade: President to sign order on psychedelic used for PTSDYahoo Finance·Apr 17, 2026
- Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical AffairsYahoo Finance·Apr 16, 2026
- Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.?Yahoo Finance·Apr 2, 2026
- Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study DataYahoo Finance·Mar 25, 2026
- Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People OfficerYahoo Finance·Mar 12, 2026
- A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety DataYahoo Finance·Mar 9, 2026
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study resultsYahoo Finance·Mar 6, 2026
- Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact?Yahoo Finance·Mar 6, 2026
All 20 articles loaded
Price Data
Open$5.23
Previous Close$5.22
Day High$5.54
Day Low$5.22
52 Week High$9.83
52 Week Low$4.29
52-Week Range
$4.29$9.83
$5.54
Fundamentals
Market Cap$276M
P/E Ratio—
EPS$-4.30
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume716K
Avg Volume (10D)—
Shares Outstanding49.9M
About Cybin Inc
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company is headquartered in Toronto, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—